These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19688946)

  • 1. High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome.
    Bonilla-Musoles FM; Raga F; Castillo JC; Sanz M; Dolz M; Osborne N
    Clin Exp Obstet Gynecol; 2009; 36(2):78-81. PubMed ID: 19688946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
    Hosseini MA; Mahdavi A; Aleyasin A; Safdarian L; Bahmaee F
    Gynecol Endocrinol; 2012 Nov; 28(11):853-5. PubMed ID: 22697477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study.
    Zeng C; Shang J; Jin AM; Wu PL; Li X; Xue Q
    Arch Gynecol Obstet; 2019 Jul; 300(1):223-233. PubMed ID: 31004220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Kolibianakis EM
    Reprod Biomed Online; 2007 Oct; 15(4):408-12. PubMed ID: 17908403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial].
    Cheng ZX; Kong G; Zhang CL; Zhao YN
    Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):9-14. PubMed ID: 32074767
    [No Abstract]   [Full Text] [Related]  

  • 9. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Tarlatzi TB; Tarlatzis BC; Lainas TG
    Reprod Biol Endocrinol; 2012 Aug; 10():69. PubMed ID: 22938051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment.
    Roulier R; Chabert-Orsini V; Sitri MC; Barry B; Terriou P
    Reprod Biomed Online; 2003 Sep; 7(2):185-9. PubMed ID: 14567887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotrophin-releasing hormone antagonists for assisted conception.
    Al-Inany H; Aboulghar M
    Cochrane Database Syst Rev; 2001; (4):CD001750. PubMed ID: 11687120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient management of severe ovarian hyperstimulation syndrome: a systematic review and a review of existing guidelines.
    Gebril A; Hamoda H; Mathur R
    Hum Fertil (Camb); 2018 Jun; 21(2):98-105. PubMed ID: 28554223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Iliadis GS; Kolibianakis EM
    Reprod Biomed Online; 2009 Jan; 18(1):15-20. PubMed ID: 19146764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.